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ABSTRACT
Introduction Preoperative anaemia is linked to poor 
postsurgical outcome, longer hospital stays, greater risk 
of complications and mortality. Currently in the UK, some 
sites have developed anaemia clinics or pathways that use 
intravenous iron to correct iron deficiency anaemia prior 
to surgery as their standard of care. Although intravenous 
iron has been observed to be effective in a variety of 
patient settings, there is insufficient evidence in its use 
in cardiac and vascular patients. The aim of this study 
is to observe the impact and effect of anaemia and its 
management in patients undergoing cardiac and vascular 
surgery. In addition, the UK Cardiac and Vascular Surgery 
Interventional Anaemia Response (CAVIAR) Study is also 
a feasibility study with the aim to establish anaemia 
management pathways in the preoperative setting to 
inform the design of future randomised controlled trials.
Methods and analysis The UK CAVIAR Study is a 
multicentre, stepped, observational study, in patients awaiting 
major cardiac or vascular surgery. We will be examining 
different haematological variables (especially hepcidin), 
functional capacity and patient outcome. Patients will be 
compared based on their anaemia status, whether they 
received intravenous iron in accordance to their hospital’s 
preoperative pathway, and their disease group. The primary 
outcomes are the change in haemoglobin levels from 
baseline (before treatment) to before surgery; and the 
number of successful patients recruited and consented 
(feasibility). The secondary outcomes will include changes in 
biomarkers of iron deficiency, length of stay, quality of life and 
postoperative recovery.
Ethics and dissemination The study protocol was approved 
by the London-Westminster Research Ethics Committee 
(15/LO/1569, 27 November 2015). NHS approval was also 
obtained with each hospital trust. The findings of the study 
will be published in peer-reviewed journals.
Trial registration number Clinical Trials 
registry (NCT02637102) and the ISRCTN registry 
(ISRCTN55032357).
INTRODUCTION
There is increasing evidence that preopera-
tive anaemia is associated with a higher risk 
of complications, prolonged hospital stay, 
transfusion requirement and mortality.1–5 
Anaemia is becoming increasingly prevalent 
largely due to an ageing population. The 
estimated prevalence of anaemia is up to 
50% of patients in some hospitals.6 There is 
also considerable variability in prevalence in 
different hospitals and regions of the UK.7 
Nutritional deficiencies of iron, folate and/
or vitamin B12 contribute to approximately 
a third of the cases preoperatively, whereas 
functional iron deficiency (FID) or iron 
restriction appears to be more common but 
its relevance is less well understood.8
FID exists when there is failure of the 
bioavailability of iron for erythrogenesis. 
The mechanism occurs via inflammatory 
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Strengths and limitations of this study
 ► This is the first study examining how iron treatment 
and major surgery affects haematological variables, 
functional capacity and patient outcome.
 ► Furthermore, this study will also be the first to 
compare cardiac with vascular patient groups.
 ► The results of this study will provide information 
in the understanding of preoperative anaemia, and 
whether correcting iron deficiency anaemia will lead 
to improved surgical outcomes.
 ► Slight variations in preoperative anaemia pathways 
used in different hospitals.
 ► Different intravenous iron will be used in different 
hospitals. 
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mediators induced by pre-existing illness or comorbid 
disease. Hepcidin, an important regulator of iron homoeo-
stasis, is upregulated under inflammatory conditions9 
and prevents export of iron from cells. This results in the 
increased uptake and retention of iron from the circu-
lation by the reticular endothelial system, thus reducing 
bioavailability of iron for erythrogenesis.10 A retrospec-
tive study by Hung and colleagues8 demonstrated an 
association of elevated hepcidin with poorer outcome in 
cardiac patients. Therefore strategies in correcting and 
managing FID may play a vital role in improving postsur-
gical outcomes.
Intravenous iron has been shown to be an effective 
treatment of anaemia in a variety of settings, including 
heart failure, inflammatory bowel disease and ortho-
paedic surgery.11–14 The Cochrane review by Gurusamy 
and colleagues15 examined the effectiveness of different 
iron therapies in patients with anaemia and concluded 
that due to significant heterogeneity and low quality of the 
trials reviewed, there were insufficient grounds to support 
the role of treating patients with intravenous iron preop-
eratively. The updated review however showed increased 
efficacy of intravenous iron in correcting haemoglobin 
levels (Hb)16 as well as treatment with intravenous iron 
showed improvement in symptoms, exercise capacity and 
quality of life, typically in patients with heart failure.11 14 
There is still insufficient evidence for the effectiveness it 
may have in cardiac patients.17
National guidelines have recommended that anaemia 
should be identified before surgery and treated if appro-
priate.18 In the UK, a number of centres have introduced 
anaemia clinics or developed preoperative anaemia 
pathways incorporating intravenous iron as part of their 
standard of care. As the current evidence for different iron 
therapies is limited and variation exists, it is important to 
understand how these treatments given preoperatively 
may affect patient fitness for surgery and outcomes.
In light of this, we have designed a study to observe 
the impact and effect of anaemia and its management 
in patients undergoing cardiac and vascular surgery. 
We also aim to assess the regional variations in preop-
erative pathways, patients’ outcomes postoperatively 
and their requirement for transfusion. In addition, this 
study aims to gather information about the feasibility of 
establishing anaemia management pathways in the preop-
erative setting to guide the design of future randomised 
controlled trials (RCTs).
METHODS AND ANALYSIS
This study is a multicentre, stepped, prospective, obser-
vational platform comprising two cohorts in patients 
awaiting major cardiac or vascular surgery. In the first 
cohort we will examine the effect of anaemia and outcomes 
(cohort 1), and in the second cohort we will assess the 
effect of treatment of anaemia (cohort 2) in both popu-
lation groups. The study is stepped, whereby cohort 1 
will initially be identified on the day of surgery and then 
following feasibility at least 10 days before operation. This 
enables a step to cohort 2 as the sites can feasibly identify 
and recruit patients in the appropriate time frame. The 
advantage of this is that the study can examine a number 
of outcome variables, and will permit calculation of the 
effect of each variable on the probability of developing 
the outcome of interest (relative risk) (please see online 
supplementary file for the STROBE checklist).19
Patients will be identified through routine clinical care, 
which, depending on the participating site, may include 
surgical outpatients, preadmission clinics, or referral 
for cardiopulmonary exercise test (CPET) or 6 min walk 
test (6MWT) prior to their planned surgery. Local clini-
cians or research nurses will screen scheduled elective 
surgery lists and their haemoglobin blood results (within 
the last 3 months) for eligible patients. Frequency of the 
screening and contact with the patient has been left to 
the discretion of the local staff as time and resources vary 
between hospitals. In addition, each site will be requested 
to recruit patients in a consecutive manner. The study 
therefore acts to be a feasibility assessment of local teams 
to identify patients for preoperative clinical trials.
Anaemia in this study satisfies WHO criteria with 
(Hb) <130 g/L in men and <120 g/L in women.20 21
Inclusion criteria are: patients aged 18 years or over, 
undergoing elective cardiac or vascular surgery (eg, coro-
nary artery bypass graft (CABG), valve surgery, repair 
or replacement of thoracic or abdominal aorta (open 
or endovascular), revascularisation or endarterectomy), 
with written informed consent.
Exclusion criteria are: patients who are pregnant or 
lactating, undergoing renal dialysis (current or planned 
within the next 12 months), prisoners and patients who 
have an underlying history of learning disabilities or 
adults who do not have mental capacity to consent for 
themselves.
Recruited patients will then be categorised as below 
(see figure 1).
1. Patients prior to major cardiac or vascular surgery, 
in whom consent is taken before operation
2. Patients prior to major cardiac or vascular surgery, 
in whom consent is taken at least 10 or more days 
before operation
3. Patients prior to major cardiac or vascular surgery, 
in whom consent is taken at least 10 or more days 
before operation in whom a functional exercise 
assessment is performed (CPET or 6MWT)
Substudy arm
In patients who receive intravenous iron as part of normal 
clinical practice at that hospital:
1. Patients who have consented for blood sampling 
(ie, additional core blood samples) before and 
after intravenous iron
2. Patients who have consented for blood sampling 
and in addition in whom a functional exercise 
assessment is performed (CPET or 6MWT) before 
and after intravenous iron
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3. Patients who have consented for blood sampling 
and in addition in whom a total haemoglobin 
mass (tHbmass) test is performed before and after 
intravenous iron
Assessments
Patient data will be obtained from medical records and 
will be used to assess the approach to anaemia manage-
ment between the participating sites. Information will 
include patients' past medical history, medications, bloods 
(including haematinics, ferritin and C reactive protein), 
CPET or 6MWT (if applicable), quantity of blood trans-
fused, length of intensive care unit (ICU) and hospital 
stay and complications relating to index surgery. Data 
will be collected from consent to prospectively during 
hospital admission, up until 4–6 weeks at routine clinic 
follow-up appointment.
In addition to the routine medical information, the 
trial will also request additional assessments (see online 
supplementary file 1). These include:
1. Additional core blood tests to examine iron status, 
hepcidin and serum proteins;
2. Health-related Quality of life (HRQoL) 
questionnaires (comprised of Single Question 
Outcome Measure, Multidimensional Fatigue 
Inventory and EuroQol in the study arm only;
3. Days alive and out of hospital (DAOH) at follow-up 
for all arms (at 30 days postsurgery), calculated as 
per Ariti and colleagues.8 22
Substudy only:
1. If CPET/6 MWT was done routinely at baseline 
before iron therapy (eg, preassessment clinic), 
we would ask the patient to repeat the same test 
after iron therapy. Both CPET and 6MWT will 
be included in this study. CPET is an objective 
measure in determining response of patients who 
undergo major surgery through quantifying oxygen 
consumption and carbon dioxide production.23 
Although it is considered the gold standard 
assessment of functional capacity, it is however not 
routinely used in all NHS hospitals. The alternative 
option is the 6MWT, which is easy to administer 
and does not require special equipment, and 
involves walking up and down a 100 ft hallway. The 
limitation to the 6MWT is that it is only a good 
indicator for daily activities and not so much on 
peak oxygen uptake.24
2. Selected sites will conduct the tHbmass test (as this 
requires special equipment and training) using 
the optimised carbon monoxide rebreathing 
method25 before and after iron therapy. 
tHbmass represents absolute mass of circulating 
haemoglobin and has been suggested to be a more 
reliable marker in determining oxygen carrying 
capacity and in predicting postsurgical outcome 
compared with using Hb or blood volume alone.26 
The test involves breathing through a tube that 
is attached to a bag containing small amounts 
of carbon monoxide for 2 min. Blood samples 
will be taken from the fingertip or earlobe 
before and after carbon monoxide exposure to 
determine carboxyhaemoglobin concentration.25 
This will be exploratory in nature to determine 
the feasibility and practicality if carried out in a 
‘hospital’ setting.
Where possible, assessments will coincide with routine 
hospital schedules and clinical blood tests. All data will 
be entered by local staff into a password-protected, elec-
tronic case report form (eCRF). Any missing data will be 
noted in the eCRF. All information collected will be kept 
confidential and in accordance with the UK Data Protec-
tion Act 1998. Figure 2 shows the flow chart of the UK 
Cardiac and Vascular Surgery Interventional Anaemia 
Response (CAVIAR) Study.
Patient outcome measures
The primary outcomes for this study are:
 ► Change in Hbfrom baseline (before treatment) to 
before surgery in the study arm; and
 ► The number of successful patients recruited and 
consented (feasibility).
The secondary outcomes are:
 ► Change in Hb from before treatment to postsurgery;
 ► Changes in biomarkers of iron deficiency (eg, 
hepcidin, ferritin, transferrin saturation) from 
before and after iron therapy,
 ► Units of blood transfused perioperatively; length of 
stay (LOS) in hospital and ICU;
 ► Renal function (change in creatinine) from baseline 
to before or after surgery; complications during 
hospital stay;
 ► HRQoL questionnaires before and after iron therapy 
(or after surgery for substudy).
Figure 1 Patient categorisation. 6MWT, 6 mins walk test; 
CPET, cardiopulmonary exercise test; IV, intravenous; 
tHbmass, total haemoglobin mass.
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 ► For the substudy only arm: CPET/6 MWT before and 
after iron therapy; and tHbMass test before and after 
iron therapy.
Sample size calculation
The sample size was calculated for the primary 
end point of change in Hb from baseline to 10–42 
days before surgery for those who receive intravenous 
iron. Assuming that the SD for Hb will be 12 g/L,7 27 
72 patients will provide 90% power at the 5% signifi-
cance level (allowing for up to 10% loss to follow-up) to 
demonstrate a difference in the change from baseline 
in Hb of 10 g/L. We will therefore recruit 72 cardiac 
surgery patients and 72 vascular surgery patients for the 
study arm (cohort 2). In patients who received intrave-
nous iron in the study arm, an arbitrary number of 12 
from each of the patient groups will be asked to partic-
ipate in the substudy arm. This substudy arm will be 
Figure 2 Flow chart of the UK CAVIAR Study. * Collected from patient’s medical records. # Only relevant for the 
substudy arm. CAVIAR, Cardiac and Vascular Surgery Interventional Anaemia Response; 6MWT, 6 min walking test; 
CPET, cardiopulmonary exercise test; DAOH, days alive and out of hospital; HRQoL, health-related quality of life; 
ICU, intensive care unit; IV, intravenous; tHbmass, total haemoglobin mass. 
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exploratory in nature, used to determine the feasibility 
and practicality to carry these additional assessments in 
a ‘hospital setting’.
For the control arm, we will recruit patients who are 
anaemic and non-anaemic (cohort 1). Controls will be 
collected sequentially for the duration of the trial to avoid 
time bias and sampling error. Therefore, control patients 
will be recruited at twice the number than the study 
group. Overall, a total of 432 patients will be recruited to 
this study. See online supplementary file 2 for the number 
of patients per group.
Statistical analysis
Baseline demographics of the patients will be described 
using summary statistics. Continuous variables will be 
summarised using the mean and SD if approximately 
normally distributed. Continuous variables that are 
not normally distributed will be summarised using the 
median and IQR. Differences between groups wil be 
assessed using two-sample t-tests for normally distributed 
variables. For variables that are not normally distrib-
uted an appropriate transformation will be carried out 
followed by a two-sample t-test. If no appropriate trans-
formation can be found a non-parametrical test will 
be used. Categorical variables will be described using 
frequency and percentage and differences between 
groups will be tested using χ2 or Fisher's exact tests as 
appropriate. The linear association between tHbmass, 
maximal oxygen consumption (Vo2) and iron indices 
will be evaluated using Pearson correlation coefficient 
and linear regression. Adjusted analyses will be carried 
out using multivariable linear regression. The accuracy 
of the subsequent model for outcome predictions will 
be determined using a receiver operating characteristic 
(ROC) curve analysis. Depending on the distribution of 
the data, liner regression (with a log transformation), 
Poisson or negative binomial model will be used to assess 
the value of preoperative tHbmass as a predictor of the 
primary outcome, postoperative morbidity and secondary 
outcome variables (hospital LOS, ICU LOS).
DISCUSSION
Preoperative anaemia is recognised in cardiac and 
vascular surgery. Anaemia is linked independently with 
worse outcome, including length of hospital stay and 
mortality. Despite studies having shown that intravenous 
iron is effective in a variety of population groups,11–14 
there is still insufficient evidence to support its use. The 
current published evidence is of low quality or too hetero-
geneous.15 Furthermore, to our knowledge there are no 
RCTs that have been conducted looking at iron therapy 
in cardiovascular patients.
The UK CAVIAR Study is an observational, multi-
centre trial, to investigate the impact of anaemia and 
its management in cardiovascular patients, and the 
feasibility to study patients in the platform for a future 
planned RCT.
There is currently limited information on how iron 
treatment and major surgery have an influence on 
haematological parameters, functional parameters and 
patient outcome in cardiovascular patients. Hepcidin, 
a key regulator of iron homoeostasis9 was observed to 
be the only haematological variable that was associated 
with worse outcome in cardiac patients; and that nearly 
half of the patients identified had FID.8 Other studies 
that examined healthy participants and athletes with or 
without anaemia and iron deficiency had reduced func-
tional capacity.28–30 It is therefore reasonable to assume 
that patients may respond to iron treatment, and may 
lead to improved outcomes. Our study is the first study 
to examine these areas and aims to provide insight on 
how intravenous iron and major surgery may influence 
hepcidin and other haematological variables, functional 
capacity and outcomes in cardiovascular patients. In 
addition, this study will also be the first to compare these 
two different, yet similar, population groups; and their 
outcomes assessed through using a composite of mortality 
and LOS in hospital (ie, DAOH).
One of the outcomes assessed in this study is patient 
DAOH at 30 days postsurgery. Traditionally in clinical 
trials, mortality and morbidity are often used as end point 
to determine treatment efficacy, however, it does not take 
into account the frequency for readmission, duration and 
severity. The DAOH is a composite score and is based on 
varying weightings placed on mortality and readmission 
factors, and therefore provides a clearer summary on the 
overall treatment effect.22
In our substudy, we are exploring tHbmass as an alter-
native marker in determining oxygen carrying capacity 
and in predicting postsurgical outcome. The insult of 
surgery puts enormous metabolic stress on the body 
and thereby an increase in the demand for oxygen is 
seen as a result. The inability to deliver enough oxygen 
to where it is needed may increase the risk of having 
poorer surgical outcomes.31 32 tHbmass represents abso-
lute mass of circulating Hb and is relatively unexplored 
in the clinical setting, particularly in cardiovascular 
patients. Although Hb is traditionally used, studies 
have shown that Hb may not be a reliable or accurate 
measure as it can be influenced by fluid shifts (eg, blood 
loss) or haemodilution, which is commonly observed in 
ICU.26 33 If tHbmass provides a stronger link over Hb 
in predicting postsurgical outcome, this will be a useful 
measure in determining which and when patients can 
go into surgery; and can also be a target in raising 
tHbmass to improve outcome.
One of the key hurdles we anticipate in this study is the 
identification and recruitment of patients in the intrave-
nous iron arm 10–42 days prior to surgery. The timeframe 
required is to allow at least 10 days for the intravenous 
iron to have an effect of increasing Hb. As resources and 
infrastructure will vary between hospitals, this feasibility 
study will therefore help build the framework in setting 
up a preoperative anaemia pathway, and to best identify 
and manage these patients.
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Correcting anaemia preoperatively is recognised as an 
integral part of patient blood management by the NHS. 
Blood use in cardiac patients has been shown to increase 
every year,34 while vascular patients on average receive 
2–3 units of blood during their hospital stay.35 The cost 
of transfusing a single unit of blood has been estimated 
to be £170 for the first unit, with the subsequent unit 
costing £162. If the number of units of blood used is 
reduced, there will be a potential saving of £146–689 
per person.36 Apart from the cost-saving, the reduction 
in blood transfused in patients will reduce the likeli-
hood of the associated worse outcomes that are often 
observed. These include postoperative infection and 
longer hospital stay.37 More importantly, for patients, 
correcting anaemia could significantly improve their 
outcome and quality of life as observed in patients with 
heart failure.11 14
The ultimate goal for this and the future RCTs is to 
have a preoperative anaemia pathway in place in every 
hospital so that patients with anaemia are identified early 
and corrected prior to surgery.
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